Triggering effects of BCG vaccine on antitumor and interleukin-1 secretory activity of T cell lymphokine-primed macrophages.
By using an in vitro model, this work demonstrates that BCG (Bacillus Calmette-Guerin) vaccine is able to trigger activation of T cell lymphokine-primed murine macrophages (Mo) for both tumoricidal cytotoxicity and interleukin-1 (IL-1) secretion. The results presented support the view that BCG vaccine may essentially activate primed, but not intact Mo; and that macrophage-mediated both antitumor and immunostimulatory effects of BCG vaccine observed in the body may be largely defined by functional activity of T-lymphocytes responsible for antigen-induced production of macrophage-activating lymphokines.
Seledtsova
G V
GV
Department of Experimental Immunology, Institute of Clinical Immunology, Novosibirsk, Russia.
Seledtsov
V I
VI
Kozlov
V A
VA
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents; D001500:BCG Vaccine / Q000494:pharmacology*; D005260:Female; D007375:Interleukin-1 / Q000378:metabolism*; D008222:Lymphokines / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D013601:T-Lymphocytes
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007375:Interleukin-1; D008222:Lymphokines